PCI boosts Ireland investment pre-Brexit with new clinical facility
Once completed, the building will span more than 75,000 square feet, including additional controlled room temperature and cold chain storage capabilities as well as clinical packaging services.
Work is set to take place over the coming months and complements PCI’s current footprint in Dublin, which was established after its acquisition of Millmount Healthcare in 2017.
Licensed by the Health Products Regulatory Authority (HPRA), the facility offers clinical storage and distribution (S&D) for the shipment of investigational medicinal products (IMP) within the EU and globally.
Other services include cold chain handling, packaging, and storage for clinical and commercial products as well as serialization services and analytical release testing.
Salim Haffar, CEO of PCI said in a statement: “Our growth strategy is focused on the continued expansion of our global network to support growing demand from our customers and providing a solution for Brexit through ongoing investment in capacity, capability expansion and talent.”
Haffar told us the company selected this location because it is close to its existing facility, in addition to the amount of local talent. The Dublin location is also its center of excellence for European operations.
"PCI Pharma Services is growing globally across all three of our sectors – development and manufacturing, clinical supplies and logistics, and commercial drug packaging technology," he added. "More specifically, our fastest growth area is our clinical supplies and logistics business, which has been expanding across Europe and where Dublin is a key site for our operations."
